RGDPEG-SB-HSA

drug-targeting conjugate developed by conjugation of SB202190 to human serum albumin (HSA) using a platinum-based linker; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Dijkers, Eli C F: 1 article (09/2006)
2.	Gonzalo, Teresa: 1 article (09/2006)
3.	Kok, Robbert J: 1 article (09/2006)
4.	Kéri, Gyorgy: 1 article (09/2006)
5.	Lacombe, Marie: 1 article (09/2006)
6.	Molema, Grietje: 1 article (09/2006)
7.	Orfi, Laszló: 1 article (09/2006)
8.	Poelstra, Klaas: 1 article (09/2006)
9.	Prakash, Jai: 1 article (09/2006)
10.	Temming, Kai: 1 article (09/2006)

Related Diseases

1.	Inflammation (Inflammations) 09/01/2006 - "We conclude that the developed RGDPEG-SB-HSA conjugates provide a novel means to counteract inflammation disorders such as rheumatoid arthritis."
2.	Rheumatoid Arthritis 09/01/2006 - "We conclude that the developed RGDPEG-SB-HSA conjugates provide a novel means to counteract inflammation disorders such as rheumatoid arthritis."